Q&A with Bob Weaver, HunterLab - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Bob Weaver, HunterLab
Bob Weaver, president of HunterLab, discusses current trends and challenges.

Pharmaceutical Technology
Volume 35, Issue 4, pp. 87

Q&A with
Bob Weaver, president of HunterLab


Bob Weaver
PharmTech:
What is the biggest industry challenge you're now facing?

Weaver:
Product color and appearance are increasingly important, but the pharmaceutical industry is still at an entry level in its integration of color-control instrumentation. Ultraviolet-visible (UV-vis) spectrophotometers are common in most companies. While they technically measure the same spectral range as the human eye, UV-vis spectrophotometers do not correlate with the way it sees color. Application-specific color spectrophotometers are routinely used by the chemical industry for production quality control of fine and specialty chemicals. However, in many pharmaceutical companies, an application-knowledge gap still exists regarding the science of color and appearance. Color-technology awareness and applied solution engineering continue to be at the forefront of our industry focus.

The US Pharmacopeia and the European Pharmacopoeia color standards are commonly used for color specification, but they only cover a small range of the color gamut as seen by the human eye. True, it is easier to add a visual test than to add an analytical-instrument step in the development and production process. However, visual indexing and validation have limitations and are by nature subjective methodology.

PharmTech:
Do you see a new industry trend emerging?

Weaver:
Today, consumers equate product quality to an expected appearance. The first things humans notice are a product's size, color, and shape. Color is an important component of branding and recognition. Increasingly, manufacturers are implementing instrumentation to ensure product color quality in many ways. Examples include measuring a lack of color in a liquid or the degree of whiteness of a compound, which correlates to purity or a lack of product degradation. Applications and technology development continue and are extending implementation to the production line.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here